Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Invested Capital (2016 - 2025)

Historic Invested Capital for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $24.2 million.

  • Sunshine Biopharma's Invested Capital fell 335.45% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 335.45%. This contributed to the annual value of $23.5 million for FY2024, which is 1081.41% up from last year.
  • Per Sunshine Biopharma's latest filing, its Invested Capital stood at $24.2 million for Q3 2025, which was down 335.45% from $25.7 million recorded in Q2 2025.
  • Sunshine Biopharma's Invested Capital's 5-year high stood at $41.9 million during Q2 2022, with a 5-year trough of -$1.2 million in Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $22.7 million (2025), whereas its average is $19.6 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Invested Capital skyrocketed by 1011797.49% in 2022, and later plummeted by 4561.36% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Invested Capital (Quarter) stood at $211662.0 in 2021, then surged by 10117.97% to $21.6 million in 2022, then fell by 1.94% to $21.2 million in 2023, then grew by 10.81% to $23.5 million in 2024, then grew by 2.97% to $24.2 million in 2025.
  • Its Invested Capital was $24.2 million in Q3 2025, compared to $25.7 million in Q2 2025 and $22.7 million in Q1 2025.